Abstract
Physiological changes in lipoprotein levels occur in normal pregnancy. Women with hyperlipoproteinemia are advised to discontinue statins, fibrates already when they consider pregnancy up to and including breast-feeding the newborn, because of the fear for teratogenic effects. Hypertriglyceridemia in pregnancy can rarely lead to acute pancreatitis. Management of acute pancreatitis in pregnant women is similar to that used in non-pregnant patients. Further large cohort studies are needed to estimate the consequence of supraphysiologic hyperlipoproteinemia or extreme hyperlipoproteinemia in pregnancy on the risk for cardiovascular disease later in life.
MeSH terms
-
Acute Disease
-
Adult
-
Breast Feeding
-
Drug Administration Schedule
-
Female
-
Fibric Acids / administration & dosage*
-
Fibric Acids / adverse effects
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hyperlipoproteinemia Type II / diagnosis
-
Hyperlipoproteinemia Type II / drug therapy
-
Hyperlipoproteinemias / blood
-
Hyperlipoproteinemias / diagnosis*
-
Hyperlipoproteinemias / drug therapy*
-
Hypertriglyceridemia / diagnosis
-
Hypertriglyceridemia / drug therapy
-
Pancreatitis / etiology
-
Pregnancy
-
Pregnancy Complications* / blood
-
Pregnancy Complications* / diagnosis
-
Pregnancy Complications* / drug therapy
-
Teratogens*
Substances
-
Fibric Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Teratogens